MedTrace Logo

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

NCT07128472 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-19

No results posted yet for this study

Summary

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Conditions

Interventions

DRUG

Humira

Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Moustafa Adam Ali El Taieb, Professor · Dermatology, Venereology and Andrology. Faculty of Medicine,Qena University

  • Eisa Mohammed Hegazy, Professor · Dermatology, Venereology and Andrology. Qena Faculty of Medicine,South Valley University

  • Mohamed Hosny Hassan, Professor · Medical Biochemistry Department,Qena Faculty of Medicine,south valley university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-01-20
Completion
2026-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128472 on ClinicalTrials.gov